ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.
Stocktwits
ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.
Stocktwits
More News
BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles
BMO Capital Markets analyst Evan David Seigerman said that the PFS miss for BNT113 “adds to a growing list of recent mRNA cancer vaccine setbacks” and is likely to pressure the stock.
Stocktwits
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
Prelude expects patient enrollment to begin in Q4 2026, starting with monotherapy dose escalation before advancing to combination cohorts.
Stocktwits
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.
Stocktwits
Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
Rocket, RegenXBio, Precision BioSciences, Kyverna and uniQure will present on Monday at a cell and gene-therapy conference.
Stocktwits
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
Stocktwits
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.
Stocktwits
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Stocktwits
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.
Stocktwits
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks
Retail traders floated Novo Nordisk, AbbVie and Eli Lilly as possible buyers, while others saw the offering as a sign Viking may go it alone.
